---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-000173"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-01-10T23:59:59+00:00"
generated_at: "2026-06-20T17:03:15.918576+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Kala Pharmaceuticals receives Nasdaq approval to transfer listing to Capital Market

## Summary
- Transfer from Nasdaq Global Select to Capital Market approved, effective Jan 11, 2023.
- Company met minimum stockholders' equity requirement (Rule 5550(b)(1)) and market value of publicly held shares (Rule 5550(a)(5)).
- Common stock continues trading under ticker KALA on the Nasdaq Capital Market.
- Listing transfer does not affect corporate governance requirements or continuous trading nature.

## SEC filing metadata
- accession: 0001558370-23-000173
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-01-10T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023000173/0001558370-23-000173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023000173/kala-20230109x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-000173
- JSON: https://secwatch.observer/filing/0001558370-23-000173.json
- Plain text: https://secwatch.observer/filing/0001558370-23-000173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.